Purpose: To evaluate efficacy and toxicity of high-dose chemotherapy (HDCT) in metastatic breast cancer (MBC). Materials and Methods: A literature search from January 1988 until July 1998 about the treatment of metastatic breast cancer with high dose chemotherapy was conducted. Results: After HDCT the overall response rate was about 80%, with 50% of complete remissions. The median survival was > 18 months. Approximately 20% of the patients experienced long-term progression-free survival. Conclusions: Although current results appear promising, randomised trials are required to determine the role of HDCT in the treatment of patients with MBC.
|Translated title of the contribution||High-dose chemotherapy in metastatic breast cancer|
|Number of pages||4|
|Publication status||Published - 1998|
ASJC Scopus subject areas